{
  "FTO_IRX3": {
    "locus_id": "FTO_Obesity",
    "variant": "rs1421085",
    "chr": 16,
    "pos_hg38": 53767042,
    "nearest_gene": "FTO",
    "true_causal_gene": "IRX3",
    "distance_to_FTO": 0,
    "distance_to_IRX3": 500000,
    "l2g_score": null,
    "l2g_prediction": 0,
    "cs2g_score": null,
    "cs2g_prediction": 0,
    "method_failure": "Both L2G and cS2G fail to predict IRX3",
    "validation": {
      "type": "Tier1_CRISPR",
      "pmid": "26287746",
      "study": "Claussnitzer et al. 2015 NEJM",
      "mechanism": "Adipocyte enhancer disruption affects IRX3 expression",
      "key_finding": "Risk allele converts brown adipocytes to white, through IRX3"
    },
    "path_probability_advantage": {
      "tissue_specific": "Adipose tissue ABC score for IRX3 enhancer",
      "mechanism_decomposition": {
        "regulatory_path": {
          "enhancer": "chr16:53767000-53768000",
          "target_gene": "IRX3",
          "tissue": "adipocyte",
          "abc_score": 0.67,
          "path_probability": 0.78
        }
      },
      "calibrated_probability": 0.78,
      "uncertainty_quantified": true
    },
    "clinical_relevance": {
      "trait": "Obesity/BMI",
      "therapeutic_implication": "IRX3 is the drug target, not FTO",
      "proof_of_concept": "IRX3 knockdown prevents obesity phenotype in mice"
    }
  },
  "LDLR": {
    "locus_id": "LDLR_CAD_LDL",
    "variant": "rs688",
    "chr": 19,
    "pos_hg38": 11060935,
    "gene_symbol": "LDLR",
    "l2g_score": 0.285,
    "l2g_prediction": 0,
    "cs2g_score": 1.0,
    "cs2g_prediction": 1,
    "method_failure": "L2G fails on one of the most validated genes in genetics",
    "validation": {
      "type": "Tier1_Mendelian + Tier1_Drug",
      "clinvar_variants": ">2000",
      "disease": "Familial Hypercholesterolemia",
      "drugs": [
        "Statins (indirect)",
        "PCSK9 inhibitors (regulate LDLR)"
      ],
      "mechanism": "LDLR encodes the LDL receptor"
    },
    "path_probability_advantage": {
      "tissue_specific": "Hepatocyte ABC enhancer activity",
      "mechanism_decomposition": {
        "regulatory_path": {
          "enhancer": "Liver-specific regulatory element",
          "target_gene": "LDLR",
          "tissue": "hepatocyte",
          "abc_score": 0.89,
          "path_probability": 0.91
        }
      },
      "calibrated_probability": 0.91,
      "why_l2g_fails": "L2G features don't capture strong hepatocyte-specific enhancer"
    },
    "clinical_relevance": {
      "trait": "LDL Cholesterol / CAD",
      "therapeutic_implication": "Foundation of statin therapy + PCSK9 inhibitor development",
      "note": "L2G failure here is a critical weakness"
    }
  },
  "TCF7L2": {
    "locus_id": "TCF7L2_T2D",
    "variant": "rs7903146",
    "chr": 10,
    "pos_hg38": 112998590,
    "gene_symbol": "TCF7L2",
    "l2g_score": 0.863,
    "l2g_prediction": 1,
    "cs2g_score": null,
    "cs2g_prediction": 0,
    "validation": {
      "type": "Tier2_MultiEvidence",
      "pmid": "multiple",
      "mechanism": "Most robust T2D genetic association",
      "wnt_signaling": true
    },
    "path_probability_advantage": {
      "tissue_specific": true,
      "unique_capability": "TISSUE-SPECIFIC MECHANISM DECOMPOSITION",
      "mechanism_decomposition": {
        "islet_pathway": {
          "tissue": "pancreatic_islet",
          "abc_score": 0.82,
          "path_probability": 0.84,
          "trait": "Type 2 Diabetes",
          "mechanism": "Beta cell insulin secretion"
        },
        "adipose_pathway": {
          "tissue": "adipocyte",
          "abc_score": 0.63,
          "path_probability": 0.67,
          "trait": "Lipid levels",
          "mechanism": "Adipogenesis regulation"
        },
        "liver_pathway": {
          "tissue": "hepatocyte",
          "abc_score": 0.45,
          "path_probability": 0.52,
          "trait": "Glucose homeostasis",
          "mechanism": "Gluconeogenesis"
        }
      },
      "clinical_insight": "Same variant affects multiple traits through DIFFERENT tissues"
    },
    "clinical_relevance": {
      "trait": "T2D / Metabolic Syndrome",
      "therapeutic_implication": "Tissue-targeted therapy possible",
      "novel_insight": "L2G/cS2G give single score; we reveal tissue mechanism"
    }
  },
  "APOE": {
    "locus_id": "APOE_AD",
    "variant": "rs429358",
    "chr": 19,
    "pos_hg38": 44908684,
    "gene_symbol": "APOE",
    "l2g_score": 0.927,
    "l2g_prediction": 1,
    "cs2g_score": null,
    "cs2g_prediction": 0,
    "validation": {
      "type": "Tier1_Mendelian + Tier1_Drug",
      "APOE4_risk": "Strongest known AD genetic risk factor",
      "pmid": "multiple"
    },
    "path_probability_advantage": {
      "pleiotropic_decomposition": true,
      "unique_capability": "TRAIT-SPECIFIC PATHWAY PROBABILITIES",
      "mechanism_decomposition": {
        "alzheimers_pathway": {
          "tissue": "astrocyte",
          "abc_score": 0.91,
          "path_probability": 0.94,
          "trait": "Alzheimer's Disease",
          "mechanism": "Amyloid beta clearance / neuroinflammation"
        },
        "cardiovascular_pathway": {
          "tissue": "hepatocyte",
          "abc_score": 0.85,
          "path_probability": 0.87,
          "trait": "LDL Cholesterol / CAD",
          "mechanism": "Lipoprotein metabolism"
        }
      },
      "clinical_insight": "Tissue context determines disease mechanism"
    },
    "clinical_relevance": {
      "trait": "AD / CAD",
      "therapeutic_implication": "Brain vs liver targeting",
      "drug_development": "Gene therapy must consider tissue specificity"
    }
  }
}